SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Similar documents
SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

NEW ZEALAND DATA SHEET

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

3 PHARMACEUTICAL FORM Coated tablet Round, white to off-white, sugar coated tablets, plain on both sides.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

Body weight more than 30kg : 10ml (10mg) of the syrup once daily.

100 ml of the syrup contain 825 mg of ivy leaf dry extract (Hedera helix L., folium) ( 4-8:1). Extraction solvent: ethanol 30% (m/m).

Used for removing granulation tissue, warts (including verrucas), for cautery and as a caustic

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

VALERIANA OFFICINALIS 445 MG COATED TABLET Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT. Lamisil 1% cutaneous solution. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. A 2.5ml single-dose bottle containing IU Cholecalciferol (equivalent to 625 micrograms vitamin D 3 )

Package Insert. Constipeg

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics Updated 01-May-2015 Meda Pharmaceuticals

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Macrovic Junior powder for oral solution contains the following active ingredients:

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

DOSAGE FORMS AND STRENGTHS White toothpaste containing 1.1% sodium fluoride (3)

PDF rendering: Titel , Version 1.1, Namn Azelastine OmniVision 0.5 mg per ml eye drops, solution SmPC

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF THE PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Summary of Product Characteristics

Summary of Product Characteristics

SUMMARY OF THE PRODUCT CHARACTERISTICS. The content of electrolyte ions per sachet when made up to 125 ml of solution.

Excipients with known effect: Each gramme of gel contains 1 mg methyl parahydroxybenzoate (E-218) and 0.5 mg propyl parahydroxybenzoate (E-216).

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS. One chewable tablet contains 1250 mg calcium carbonate (equivalent to 500 mg calcium).

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory ZODERM E CREAM. Oxiconazole Nitrate Cream

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory. Light Liquid Paraffin and White Soft Paraffin Cream

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Summary of Product Characteristics

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT

SUMMARY OF PRODUCT CHARACTERISTICS. Synthamin 14, 8.5% Amino Acid Intravenous Infusion

1. NAME OF THE MEDICINAL PRODUCT. Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Summary of Product Characteristics

Package Insert. D-Bright

NEW ZEALAND DATA SHEET

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Article 30 Referral for Calcitugg (and associated names) Chewable tablets (Calcium carbonate)

Fixed combination of Valeriana officinalis L., radix (valerian root) and Humulus lupulus L., flos (hop strobile).

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

Instil one or two drops in the conjunctival sac(s) every three to four hours as needed.

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF THE PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

NEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.

SUMMARY OF THE PRODUCT CHARACTERISTICS

Dosage in renal impairment Kalcipos-D chewable tablets should not be used in patients with severe renal impairment.

Emergency contraception is an occasional method. It should in no instance replace a regular contraceptive method.

SUMMARY OF PRODUCT CHARACTERISTICS

Ketosteril. Total nitrogen content per tablet

SUMMARY OF PRODUCT CHARACTERISTICS

Indications: For the treatment and control of fascioliasis in cattle and sheep.

Once applied, Sitavig stays in position and gradually dissolves during the day.

Summary of product characteristics (SmPC)

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS. Albuman 40 g/l is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin.

SUMMARY OF PRODUCT CHARACTERISTICS

Health Products Regulatory Authority

Produktinformationen för Bentifen, 0,25 mg/ml, Ögondroppar, lösning, endosbehållare, MTnr 16252, gäller vid det tillfälle då läkemedlet godkändes.

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Transcription:

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fluoride 2800 ppm Toothpaste 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g of toothpaste contains contains 2.8 mg fluoride (as sodium fluoride), corresponding to 2800 ppm fluoride, sodium fluoride 0.619 % w/w. Excipient(s) with known effect: Sorbitol solution (non-crystallising) Propylene glycol For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Toothpaste. For dental use. Smooth, white coloured paste with the odour and taste of spearmint. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Fluoride 2800 ppm Toothpaste is indicated in adolescents, and children aged 10 years and over. Prevention and treatment of dental caries (coronal and root) adolescents and children aged ten years or more. 4.2 Posology and method of administration Posology Paediatric population: Fluoride 2800 ppm Toothpaste is contraindicated in children aged under 10 years, see section 4.3. Adolescents and children aged 10 years or more: To be used daily instead of the normal toothpaste. Brush carefully and thoroughly, for one minute, morning and evening:

- Apply a 1 cm ribbon of toothpaste onto the toothbrush for each brushing - Brush teeth vertically, from the gum to the tip of the teeth - Careful brushing takes approximately one minute - Spit out after use - For best results do not drink or rinse for 30 minutes Not to be swallowed. Method of administration For dental use. For oromucosal use only. 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Use by children aged under ten years, see section 4.2. 4.4 Special warnings and precautions for use Not to be swallowed. An increased number of potential fluoride sources may lead to fluorosis. In order to prevent the accumulation of fluoride, the total fluoride intake must be assessed before this fluoride toothpaste is used. When carrying out overall calculations of the recommended fluoride ion intake, which is 0.05 mg/ Kg body weight per day from all sources, not exceeding 1 mg per day, allowance must be made for possible ingestion of toothpaste (each 75 ml tube of Fluoride 2800 ppm Toothpaste contains 280 mg of fluoride ions). This product contains propylene glycol. Propylene glycol may cause skin irritation. This product also contains Sorbitol solution. Patients with rare hereditary problems of fructose intolerance should not take this medicine. Paediatric population This product should not be used by children aged under ten years, see sections 4.2 and 4.3. 4.5 Interaction with other medicinal products and other forms of interaction No interaction studies have been performed. 4.6 Fertility, pregnancy and lactation Epidemiological studies in humans indicate that fluoride has no adverse effects in pregnancy or on the health of the foetus or new born child. Fluoride 2800 ppm Toothpaste can be used during pregnancy and lactation.

Studies in animals have shown reproductive toxicity of sodium fluoride only when administered at very high levels (see section 5.3). 4.7 Effects on ability to drive and use machines Fluoride 2800 ppm Toothpaste has no or negligible influence on the ability to drive and use machines. 4.8 Undesirable effects Immune system disorders: Rare (> 1 / 10,000, < 1 / 1,000): hypersensitivity reactions. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system, the Yellow card scheme at: www.mhra.gov.uk/yellowcard. 4.9 Overdose Acute Intoxication: The toxic dose, i.e the lowest dose at which symptoms of intoxication can be induced, is 5 mg fluoride per Kg body weight. Such intoxication appears in the form of digestive problems: vomiting, diarrhoea, abdominal pain. In extremely rare cases it can prove fatal. Treatment: where a substantial quantity of the medicinal product is ingested accidentally, the patient will need to undergo gastric lavage immediately, or vomiting will need to be induceed; calcium needs tyo be taken (large amount of milk), and the patient will require to be kept under medical observation for several hours. Chronic Intoxication (Fluorosis): The dental enamel will take on a stained or speckled appearance once a fluoride dosage in excess of 1.5 mg per day is absorbed daily over several months or years, depending on the extent of overdose. This will be accompanied by increased enamel fragility in severe forms. Bone fluorosis (osteosclerosis) will only be seen where there is high chronic absorption of fluoride (over 8 mg daily).

5 PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties Pharmacotherapeutic group: caries prophylactic agents ATC code: A01AA01 This product is a toothpaste in which the active ingredient is sodium fluoride present at a level of 0.619 % w/w, which corresponds to 280 mg fluoride per 100 g toothpaste. Sodium fluoride applied topically after tooth eruption reduces caries by inhibiting demineralisation and promoting remineralisation of the tooth surface. It is effective on both enamel and exposed dentine. 5.2 Pharmacokinetic properties Fluoride 2800 ppm FluorideTtoothpaste has a local, topical action on the teeth and so the route taken within the body does not apply. This product is not intended to be swallowed and therefore only minimal systemic exposure is expected. However, the following information has been included in case any toothpaste is accidentally ingested during treatment. Absorption Ingested fluride is converted to hydrofluoric acid. Peal concentrations are achieved within 30 60 minutes. Distribution The volume of distribution is 1 L / Kg. Fluoride ions are distributed to teeth and bones, and are not bound to plasma proteins. Biotransformation Ingested fluride is converted to hydrofluoric acid. Elimination The terminal half life is in the range 2 9 hours. Fluoride ions are excreted mainly in urine, but small amounts may also be excreted in faeces and sweat. It is not known in which form. 5.3 Preclinical safety data Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.

After oral administration of sodium fluoride to mice, rates and rabbits, reproductive and foeto toxic effects were observed only at high dose levels. The total amount of fluoride in a 75 ml tube of Fluoride 2800 ppm Toothpaste is about 620 mg which equates to 280 mg fluoride. This is within the acceptable limits for the amount to be supplied at one time for safety purposes. 6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients Sorbitol solution (non-crystallising), E420 Glycerol, E422 Dental type silica (precipitated), E551 Macrogol 600, E1521 Sodium laurilsulphate Carmellose sodium, E466 Sodium saccharin, E954 Titanium dioxide, E171 Mint flavour (947093 Optamint Spearmint) containing menthol, propylene glycol, spearmint oil, carvone, anethol, ethyl maltol, vanillin Purified water 6.2 Incompatibilities Not applicable. 6.3 Shelf life Thirty six (36) months unopened. 6 months after opening. 6.4 Special precautions for storage This product requires no special storage conditions.

6.5 Nature and contents of container Polyethylene/copolymer/aluminium/copolymer/polyethylene laminated tube with a polypropylene flip top closure. 75ml. 6.6 Special precautions for disposal Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 7 MARKETING AUTHORISATION HOLDER Morningside Healthcare Ltd, 115 Narborough Road, Leicester, LE3 0PA, United Kingdom 8 MARKETING AUTHORISATION NUMBER(S) PL 20117/0239 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 10/12/2014 10 DATE OF REVISION OF THE TEXT 22/07/2015